Ceftazidime therapy for serious infections.

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Severe infections pose significant treatment challenges.
• Ceftazidime is a third-generation cephalosporin antibiotic.
• Evaluating antibiotic efficacy in diverse patient populations is crucial.

Purpose of the Study:

• To assess the efficacy and safety of parenteral ceftazidime in treating severe infections.
• To evaluate treatment outcomes in specific patient groups, including cystic fibrosis and peritoneal dialysis patients.
• To determine ceftazidime's pharmacokinetic profile in blood, peritoneal dialysis fluid, and sputum.

Main Methods:

• Retrospective analysis of 32 severe infection episodes in 23 patients treated with ceftazidime.
• Categorization of infections by type and patient population.
• Monitoring of clinical response, pathogen identification, and adverse effects.

Main Results:

• 96% of all severe infections showed clinical cure or improvement.
• 14 of 15 chest infections in cystic fibrosis patients responded well, with identified pathogens including Pseudomonas aeruginosa and Staphylococcus aureus.
• All 7 cases of peritonitis in peritoneal dialysis patients were successfully treated.
• Good drug levels were achieved in blood and peritoneal dialysis fluid, with sputum penetration observed.
• Adverse effects were minimal and not severe.

Conclusions:

• Parenteral ceftazidime demonstrates high efficacy in treating a range of severe infections.
• The antibiotic is particularly effective in cystic fibrosis patients and those with peritonitis.
• Ceftazidime exhibits favorable pharmacokinetic properties, supporting its use in these clinical scenarios.